Biomarkers play a major role in the design of clinical trials. While some have a long and storied history, many more have built quick momentum across multiple tumors, including a number in the pan-tumor setting. As our understanding of the molecular underpinnings of cancer increases, so will the extent and breadth of new biomarker-driven trials. View a select group of biomarkers across a variety of solid and hematologic tumors.